Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001604867-25-000004
Filing Date
2025-02-14
Accepted
2025-02-14 13:00:09
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8342
2 fenc_ex1.pdf EX-1 47933
  Complete submission text file 0001604867-25-000004.txt   76481
Mailing Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709
Business Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 (919) 636-4530
FENNEC PHARMACEUTICALS INC. (Subject) CIK: 0001211583 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-80470 | Film No.: 25625981
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 1063 POST ROAD 2ND FLOOR DARIEN CT 06820
Business Address 1063 POST ROAD 2ND FLOOR DARIEN CT 06820 203-625-1300
Solas Capital Management, LLC (Filed by) CIK: 0001604867 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A